Tosymra® is a prescription medicine used to treat acute migraine with or without aura in adults.

Tosymra® is not used to treat other types of headaches such as hemiplegic (that make you unable to move on one side of your body) or basilar (rare form of migraine with aura) migraines. Tosymra® is not used to treat cluster headaches.

Tosymra® is not used to prevent or decrease the number of migraines you have. It is not known if Tosymra® is safe and effective in children under 18 years of age.

Migraine pain relief in as little as 10 minutes

Some patients experience migraine pain relief in as little as 10 minutes with just one spray (13% vs. 5% for placebo).†1-3

Efficacy of Tosymra® is based on relative bioavailability to subcutaneous sumatriptan at a dose of 4 mg. In a clinical study, this dose of sumatriptan resulted in 57% of patients achieving pain relief at 2 hours vs. 21% for placebo.

†Time to onset and degree of pain relief varies by patient.

Learn More

Get Tosymra® through Cove telemedicine

There’s another way to get acute migraine treatment prescribed.

Learn more
blink pharmacy plus logo

Tosymra® for as little as $0*

Eligible commercially insured patients may pay as little as $0* per prescription, per month with free home delivery through Blink Pharmacy Plus.

*Restrictions and quantity limits apply.  Click to view complete program terms and conditions. Medicare, Medicaid, and other federal and state healthcare program patients are not eligible.

Savings Program

Tosymra® is simple to use

Watch the Instructions for Use video to learn how to use Tosymra®.

Please see Important Safety Information; full Prescribing Information, including Patient Information; and Instructions for Use.

References

  1. Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
  2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
  3. Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.